Cormorant Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Cormorant Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-295,600	Closed	-$13.9M	–	75
2019 Q4	$13.9M	Hold	295,600	–	–	0.55%	45
2019 Q3	$6.99M	Sell	295,600 -54,400	-16%	-$1.61M	0.43%	52
2019 Q2	$10.5M	Sell	350,000 -50,000	-13%	-$1.15M	0.6%	47
2019 Q1	$8.96M	Sell	400,000 -41,000	-9%	-$881K	0.61%	43
2018 Q4	$8.03M	Buy	+441,000	New	+$6.92M	0.65%	40

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cormorant Asset Management's RARX Position: Q1 2020 in Review

Cormorant Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 295,600 shares — an estimated $13.9M sold.

Cormorant Asset Management first reported a position in RARX in Q4 2018 and held it in 5 quarters. The position peaked at $13.9M in Q4 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

Cormorant Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Cormorant Asset Management sold 295,600 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $13.9M.
Cormorant Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
Cormorant Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $13.9M in Q4 2019.
144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Cormorant Asset Management's 13F filing for Q1 2020, filed 15 May 2020.